Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of hzVSF-v13 in Healthy Male Volunteers
NCT03653208Phase 1Completed
- Sponsor
- ImmuneMed Inc.
- Start
- Nov 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of burfiralimab in Chronic Hepatitis B (CHB) and influenza (9 arms), sponsored by ImmuneMed Inc. Primary endpoint: Safety and Tolerability Assessments by Vital Signs at 2184 hours. Started Nov 2018; status: completed.
02
Drugs
burfiralimab
03
Conditions
Chronic Hepatitis B (CHB)influenza
Beyond the preview
Go deeper on NCT03653208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03653208.